Health Info & News
Adam In Depth Patient Reports provided by 
Complete Index | Default
All [0-9] A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
 |
Acute lymphocytic leukemia 01/16/2007
Acute lymphoblastic (or lymphocytic) leukemia Highlights: Drug Approvals Imatinib (Gleevec) is approved for treating Philadelphia chromosome-positive acute lymphocytic leukemia (ALL) that has not responded to treatment, or has returned after treatment. Dasatinib (Sprycel) is approved for patients with Philadelphia chromosome-positive ALL who are resistant to imatinib. |
|
Alcoholism 12/03/2006
Alcohol dependence; Alcohol abuse Highlights: Drug Approval In 2006, the FDA approved Vivitrol, a once-a-month injectable form of the anti-craving drug naltrexone. Naltrexone is also available as ReVia, a daily pill. Doctors hope that the monthly injection will provide an easier option for some patients. Outpatient Treatment For Alcoholism Alcoholism can successfully be treated in a doctor’s office, according to an important 2006 study in the Journal of the American Medical Association . |
|
Allergic rhinitis 03/22/2007
Hay fever; Nasal congestion - allergies Highlights: Drug Approval Ciclesonide (Omanaris), a corticosteroid nasal spray, has been approved for treatment of seasonal and perennial allergic rhinitis (hay fever) in adults and children age 12 years and older. FDA Drug Warnings The antihistamine promethazine (Phenergan) should not be given to children younger than age 2 because it may cause serious breathing problems. |
|
Alzheimer's disease 07/31/2007
Alzheimer's disease Description: An in-depth report on the causes, diagnosis, and treatment of Alzheimer's disease. Highlights: Alzheimer’s Disease Toll Increasing More than 5 million Americans now have Alzheimer’s disease, and the number could increase to 16 million by mid-century, according to a 2007 report from the Alzheimer’s Association. New Drug Indication In 2006, the FDA expanded the use of donepezil (Aricept) to include treatment of people with severe dementia associated with Alzheimer’s disease. |
|
Anemia 01/17/2007
Iron deficiency; Pernicious anemia Highlights: Erythropoiesis-Stimulating Drugs In 2006, the Food and Drug Administration (FDA) issued an advisory regarding treatment targets for erythropoiesis-stimulating drugs. These drugs include epoetin alfa (Procrit, Epogen, and Eprex) and darbepoetin alfa (Aranesp). They are used to treat severe anemia caused by other diseases, such as chronic kidney disease. |
|
Anxiety disorders 12/04/2006
Obsessive-compulsive disorder; Panic disorder; Phobias; Post-traumatic stress disorder Highlights: Anxiety Disorders and Physical Health Anxiety disorders affect more than emotional health -- they are also associated with many physical illnesses, suggests important new research in the Archives of Internal Medicine . Researchers found an association between anxiety disorders and thyroid, respiratory, gastrointestinal, arthritis, migraine, and allergic conditions. |
|
Asthma in adults 03/27/2007
Asthma in adults Description: An in-depth report on how asthma is diagnosed, treated, and managed in adults. Highlights: Drug Warning In 2007, the FDA requested the manufacturers of omalizumab (Xolair) to include a “boxed warning” emphasizing that this drug may cause a severe and life-threatening allergic reaction (anaphylaxis). Omalizumab is approved for patients who have moderate-to-severe asthma related to allergies and whose symptoms are not controlled by inhaled corticosteroids. It is given by injection in a doctor’s office every 2 - 4 weeks. |
|
Asthma in children and adolescents 03/26/2007
Asthma in children and adolescents Description: An in-depth report on how asthma is diagnosed, treated, and managed in children and adolescents. Highlights: Drug Warning In 2007, the FDA requested the manufacturers of omalizumab (Xolair) to include a “boxed warning” emphasizing that this drug may cause a severe and life-threatening allergic reaction (anaphylaxis). Health care providers need to carefully observe patients for 2 hours after they receive an omalizumab injection. However, because an allergic reaction can occur up to 24 hours after the injection, patients need to know the signs and symptoms of anaphylaxis and how to self-administer emergency treatment. |
|
Attention deficit hyperactivity disorder 03/05/2007
Attention deficit hyperactivity disorder Description: An in-depth report on the causes, diagnosis, treatment, and prevention of ADHD. Highlights: Drug Approval In 2006, Daytrana was approved as the first skin patch medication for treatment of attention deficit hyperactivity disorder (ADHD). Daytrana contains methylphenidate, the same drug used in Ritalin pills. Drug Warning All ADHD stimulant medications now carry warnings that patients with a history of structural heart problems, high blood pressure, or disturbances in heart rhythm (arrhythmia) should not use these drugs. |